Unknown

Dataset Information

0

Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.


ABSTRACT: The Th1 and Th2 T cell responses that underlie inflammatory bowel diseases (IBDs) are likely to depend on NF-kappaB transcriptional activity. We explored this possibility in studies in which we determined the capacity of NF-kappaB decoy oligodeoxynucleotides (decoy ODNs) to treat various murine models of IBD. In initial studies, we showed that i.r. (intrarectal) or i.p. administration of decoy ODNs encapsulated in a viral envelope prevented and treated a model of acute trinitrobenzene sulfonic acid-induced (TNBS-induced) colitis, as assessed by clinical course and effect on Th1 cytokine production. In further studies, we showed that NF-kappaB decoy ODNs were also an effective treatment of a model of chronic TNBS-colitis, inhibiting both the production of IL-23/IL-17 and the development of fibrosis that characterizes this model. Treatment of TNBS-induced inflammation by i.r. administration of NF-kappaB decoy ODNs did not inhibit NF-kappaB in extraintestinal organs and resulted in CD4+ T cell apoptosis, suggesting that such treatment is highly focused and durable. Finally, we showed that NF-kappaB decoy ODNs also prevented and treated oxazolone-colitis and thus affect a Th2-mediated inflammatory process. In each case, decoy administration led to inflammation-clearing effects, suggesting a therapeutic potency applicable to human IBD.

SUBMITTER: Fichtner-Feigl S 

PROVIDER: S-EPMC1257534 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7050625 | biostudies-literature
| S-EPMC5444015 | biostudies-literature
| S-EPMC6886797 | biostudies-literature
| S-EPMC6218406 | biostudies-other
| S-EPMC1924495 | biostudies-literature
| S-EPMC1727068 | biostudies-other
| S-EPMC8178147 | biostudies-literature
| S-EPMC3172697 | biostudies-literature
| S-EPMC1482593 | biostudies-literature
| S-EPMC5476698 | biostudies-literature